{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:14:48Z","timestamp":1778710488445,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["31301131"],"award-info":[{"award-number":["31301131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["31741084"],"award-info":[{"award-number":["31741084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005046","name":"Nature Science Foundation of Heilongjiang Province","doi-asserted-by":"crossref","award":["C201431"],"award-info":[{"award-number":["C201431"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005046","name":"Nature Science Foundation of Heilongjiang Province","doi-asserted-by":"crossref","award":["B2015005"],"award-info":[{"award-number":["B2015005"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Basic Science Fundation of Science and Technology Innovation Commission in Shenzhen","award":["JCYJ20170811154452255"],"award-info":[{"award-number":["JCYJ20170811154452255"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.canlet.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T14:57:53Z","timestamp":1528469873000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma"],"prefix":"10.1016","volume":"432","author":[{"given":"Huayi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengtong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-5604","authenticated-orcid":false,"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.06.009_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2015.11.026","article-title":"SnapShot: renal cell carcinoma","volume":"163","author":"Turajlic","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2018.06.009_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","article-title":"Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity","volume":"67","author":"Shuch","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2018.06.009_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s003450000191","article-title":"Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer","volume":"19","author":"Heinzer","year":"2001","journal-title":"World Journal of Urology"},{"key":"10.1016\/j.canlet.2018.06.009_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/CAD.0b013e3283609ec1","article-title":"Chemotherapy in metastatic renal cell carcinoma today? A systematic review","volume":"24","author":"Buti","year":"2013","journal-title":"Anti Canc. Drugs"},{"key":"10.1016\/j.canlet.2018.06.009_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1097-2765(01)00367-7","article-title":"ASPP proteins specifically stimulate the apoptotic function of p53","volume":"8","author":"Samuels-Lev","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2018.06.009_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5009\/gnl.2010.4.2.292","article-title":"Mutational analysis of ASPP1 and ASPP2 genes, a p53-related gene, in gastric and cololorectal cancers with microsatellite instability","volume":"4","author":"Park","year":"2010","journal-title":"Gut Liver"},{"key":"10.1016\/j.canlet.2018.06.009_bib7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1097-2765(01)00367-7","article-title":"ASPP proteins specifically stimulate the apoptotic function of p53","volume":"8","author":"Samuels-Lev","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2018.06.009_bib8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.4161\/cc.5.19.3266","article-title":"ASPP2: a gene that controls life and death in vivo","volume":"5","author":"Vives","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2018.06.009_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hep.23247","article-title":"Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma","volume":"51","author":"Zhao","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2018.06.009_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2403300","article-title":"Abnormal mRNA expression of ASPP members in leukemia cell lines","volume":"18","author":"Liu","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.06.009_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.devcel.2010.06.003","article-title":"ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development","volume":"19","author":"Sottocornola","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2018.06.009_bib12","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbrc.2016.12.027","article-title":"Delta N-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival","volume":"482","author":"Van Hook","year":"2017","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.canlet.2018.06.009_bib13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/ncb3050","article-title":"ASPP2 controls epithelial plasticity and inhibits metastasis through beta-catenin-dependent regulation of ZEB1","volume":"16","author":"Wang","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2018.06.009_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.412","article-title":"Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2","volume":"7","author":"Wang","year":"2016","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.canlet.2018.06.009_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.04.002","article-title":"ASPP2 suppresses invasion and TGF-beta1-induced epithelial-mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer","volume":"398","author":"Gen","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.06.009_bib16","first-page":"611","article-title":"Drug resistance: the mechanistic link and clinical implications, Nature reviews","volume":"14","author":"Shibue","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.06.009_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"Drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.06.009_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2018.06.009_bib19","first-page":"2852","article-title":"Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas","volume":"54","author":"Shuin","year":"1994","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.009_bib20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.cdd.4401962","article-title":"The p53-Bcl-2 connection","volume":"13","author":"Hemann","year":"2006","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.canlet.2018.06.009_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15252\/embr.201541809","article-title":"Histones and histone modifications in perinuclear chromatin anchoring: from yeast to man","volume":"17","author":"Harr","year":"2016","journal-title":"EMBO Reports"},{"key":"10.1016\/j.canlet.2018.06.009_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1471-2407-8-381","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer","volume":"8","author":"Fritzsche","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2018.06.009_bib23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.7150\/jca.18762","article-title":"ZEB1 mediates drug resistance and EMT in p300-deficient CRC","volume":"8","author":"Lazarova","year":"2017","journal-title":"J. Canc."},{"key":"10.1016\/j.canlet.2018.06.009_bib24","first-page":"7064","article-title":"Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma","volume":"49","author":"Hashimura","year":"1989","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.009_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.cdd.4401562","article-title":"ASPP1 and ASPP2 are new transcriptional targets of E2F","volume":"12","author":"Fogal","year":"2005","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.canlet.2018.06.009_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrc1818","article-title":"ASPPs and cancer","volume":"6","author":"Trigiante","year":"2006","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2018.06.009_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.cdd.4401536","article-title":"Apoptosis-stimulating protein of p53-2 (ASPP2\/(53BP2L)) is an E2F target gene","volume":"12","author":"Chen","year":"2005","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.canlet.2018.06.009_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.molmed.2006.02.002","article-title":"E2F1-induced apoptosis: turning killers into therapeutics","volume":"12","author":"Stanelle","year":"2006","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2018.06.009_bib29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.06.009_bib30","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1039\/C4MD00147H","article-title":"Protein\u2013protein interactions of ASPP2: an emerging therapeutic target","volume":"5","author":"Iosub-Amir","year":"2014","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.canlet.2018.06.009_bib31","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1093\/nar\/gkn490","article-title":"Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax","volume":"36","author":"Patel","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2018.06.009_bib32","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/ijc.30852","article-title":"Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2018.06.009_bib33","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/MCB.24.3.1341-1350.2004","article-title":"ASPP1 and ASPP2: common activators of p53 family members","volume":"24","author":"Bergamaschi","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2018.06.009_bib34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.canlet.2018.06.009_bib35","first-page":"1799","article-title":"Tumor-suppressor P53 is a regulator of Bcl-2 and bax gene-expression in-vitro and in-vivo","volume":"9","author":"Miyashita","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.06.009_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.276","article-title":"CHOP mediates ASPP2-induced autophagic apoptosis in hepatoma cells by releasing Beclin-1 from Bcl-2 and inducing nuclear translocation of Bcl-2","volume":"5","author":"Liu","year":"2014","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.canlet.2018.06.009_bib37","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.06.009_bib38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.15252\/emmm.201404396","article-title":"ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat","volume":"7","author":"Meidhof","year":"2015","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.canlet.2018.06.009_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2407-12-91","article-title":"EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer","volume":"12","author":"Haslehurst","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2018.06.009_bib40","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1158\/1078-0432.CCR-17-0466","article-title":"ATF3 repression of bcl-XL determines apoptotic sensitivity to HDAC inhibitors across tumor types, clinical cancer research","volume":"23","author":"Chueh","year":"2017","journal-title":"An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2018.06.009_bib41","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2018.06.009_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrd.2016.256","article-title":"Marked for death: targeting epigenetic changes in cancer, Nature reviews","volume":"16","author":"Pfister","year":"2017","journal-title":"Drug discovery"},{"key":"10.1016\/j.canlet.2018.06.009_bib43","doi-asserted-by":"crossref","first-page":"44505","DOI":"10.18632\/oncotarget.9887","article-title":"Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer","volume":"7","author":"Alzoubi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.06.009_bib44","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-08-2999","article-title":"On vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer","volume":"15","author":"Fakih","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.009_bib45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2016.04.013","article-title":"Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer","volume":"119","author":"Chan","year":"2016","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.canlet.2018.06.009_bib46","doi-asserted-by":"crossref","first-page":"9347","DOI":"10.1007\/s13277-015-3497-9","article-title":"Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase","volume":"36","author":"Liao","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.canlet.2018.06.009_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10637-013-9983-2","article-title":"Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer","volume":"32","author":"Yoo","year":"2014","journal-title":"Invest. N. Drugs"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518304075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518304075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T08:47:59Z","timestamp":1661417279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518304075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":47,"alternative-id":["S0304383518304075"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.06.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}